Relief Therapeutics Holding SA (RLFTF)
| Previous Close | 1.4500 |
| Open | 1.3300 |
| Bid | N/A x N/A |
| Ask | N/A x N/A |
| Day's Range | 1.3300 - 1.4500 |
| 52 Week Range | 0.0140 - 8.4000 |
| Volume | |
| Avg. Volume | 2,837 |
| Market Cap | 17.717M |
| Beta (5Y Monthly) | -14.37 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -8.0600 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
ACCESSWIRERELIEF THERAPEUTICS Holding SA to Hold Extraordinary General Meeting
Relief Therapeutics Calls Extraordinary General MeetingAnticipated Board of Directors Overhaul GENEVA, SWITZERLAND / ACCESSWIRE / March 27, 2024 / RELIEF THERAPEUTICS Holding SA (SIX:RLF)(OTCQB:RLFTF)(OTCQB:RLFTY) (Relief Therapeutics, or the Company), ...
- ACCESSWIRE
Relief Therapeutics Enters into Exclusive U.S. License and Supply Agreement with Eton Pharmaceuticals for PKU GOLIKE
GENEVA, SWITZERLAND / ACCESSWIRE / March 22, 2024 /RELIEF THERAPEUTICS Holding SA (SIX:RLF)(OTCQB:RLFTF)(OTCQB:RLFTY ) (Relief, or the Company), a biopharmaceutical company committed to delivering innovative treatment options for select specialty, ...
GlobeNewswireEton Pharmaceuticals Announces Acquisition of PKU GOLIKE® for Phenylketonuria
PKU GOLIKE® is a commercial ultra-rare disease medical formula complementary to Eton's existing metabolic franchise and specialty call pointTransaction is expected to be accretive to 2024 earningsEstimated peak sales of more than $10 million annuallyU.S. phenylketonuria ("PKU") medical formula market estimated to be $100 million annually DEER PARK, Ill., March 22, 2024 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or the “Company”) (Nasdaq: ETON), an innovative pharmaceutical company foc
